US FDA approval for Alexion’s Myasthenia Gravis Treatment, Soliris

Alexion has finally claimed FDA approval for its complement inhibitor Soliris in Myasthenia Gravis (MG), which could potentially add $1bn-plus in peak sales for the product. The US regulator has approved Soliris (Eculizumab) to treat adults with refractory generalised MG who are anti-acetylcholine receptor (AchR) antibody-positive, a patient group that “continues to suffer from significant

Continue Reading